Literature DB >> 28121361

The role of oxidative stress in the relation between fibromyalgia and obstructive sleep apnea syndrome.

T Yildirim1, R Alp.   

Abstract

OBJECTIVE: The aim of this study is to examine the involvement of oxidative and antioxidative parameters and to evaluate the relation between fibromyalgia (FMS) and obstructive sleep apnea syndrome (OSAS). PATIENTS AND METHODS: Oxidative stress was determined by measuring the levels of malondialdehyde (MDA) and antioxidative parameters (superoxide dismutase [SOD], catalase [CAT], and glutathione peroxidase [GPx]) in 131 randomly selected patients with OSAS. The control group was composed of 129 subjects with no clinical OSAS symptoms. OSAS was diagnosed by polysomnographic tests. All patients underwent overnight polysomnographic recording. The diagnosis of fibromyalgia was made following the diagnostic criteria of the American College of Rheumatology. The FMS patients used visual analog scales (VAS) to evaluate their pain, and they completed the FMS Impact Questionnaire (FIQ). All subjects completed the 36-item Short Form Health Survey (SF-36) and the Beck Depression Inventory (BDI).
RESULTS: In the OSAS + FMS group, CAT, SOD, and GDX were found to be statistically significantly lower and MDA was found to be statistically significantly higher than in both the control group and the OSAS group (p = 0.0001). A significant difference was found about gender between the OSAS group and the OSAS+FMS group (p = 0.0001). In the OSAS + FMS group, BDI was found to be statistically significantly higher than in both the control group and the OSAS group (p = 0.0001). In the OSAS + FMS group, SF 36 was found to be statistically significantly higher than in both the control group and the OSAS group (p = 0.0001). No differences were observed between the groups about AHI, minimum O2 saturation, or total sleep time values. About the presence of FMS presence, no differences were detected among the mild, moderate, and severe OSAS groups (p = 0.831). A negative correlation was determined between AHI and VAS and total sleep and sensitive points (p = 0.0001). A negative correlation was shown between CAT and GPX, SOD and apnea/hypopnea index (AHI) (p = 0.0001). A positive correlation was shown between CAT, GPX and SOD (p = 0.0001). A minimum O2 saturation was detected. A positive correlation between MDA and AHI (p = 0.0001), and a negative correlation between MDA and O2 saturation (p = 0.0001) were found.
CONCLUSIONS: OSAS and FMS were highly prevalent, which indicated that oxidative stress might play a role in the pathophysiology of both diseases, especially if they co-exist in the same patient.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28121361

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  Serum Romo1 is significantly associated with disease severity in patients with obstructive sleep apnea syndrome.

Authors:  Liang Ye; Yingying Qian; Qian Li; Surong Fang; Zhenhua Yang; Yan Tan; Wei Gu
Journal:  Sleep Breath       Date:  2018-01-04       Impact factor: 2.816

2.  Involvement of TRPM2 and TRPV1 channels on hyperalgesia, apoptosis and oxidative stress in rat fibromyalgia model: Protective role of selenium.

Authors:  Esra Yüksel; Mustafa Nazıroğlu; Mehmet Şahin; Bilal Çiğ
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

3.  Relationship of locomotive syndrome with health-related quality of life among patients with obstructive sleep apnea syndrome.

Authors:  Hiroaki Kataoka; Nobuyuki Miyatake; Hirohisa Ichikawa; Yukako Arakawa; Yoshihiro Mori
Journal:  J Phys Ther Sci       Date:  2017-07-15

Review 4.  Circulating Malondialdehyde Concentrations in Obstructive Sleep Apnea (OSA): A Systematic Review and Meta-Analysis with Meta-Regression.

Authors:  Maria Carmina Pau; Elisabetta Zinellu; Sara S Fois; Barbara Piras; Gianfranco Pintus; Ciriaco Carru; Arduino A Mangoni; Alessandro G Fois; Angelo Zinellu; Pietro Pirina
Journal:  Antioxidants (Basel)       Date:  2021-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.